r/insiderData | reddlx

▲ 192 r/insiderData+105 crossposts

Most people who followed $CYDY remember March 30, 2021. The FDA publicly stated that CytoDyn's claims about leronlimab were "misleading and not supported by the data", no benefit was shown in COVID-19 treatment trials. The stock dropped 25%+ that day.

What happened afterward was a class action lawsuit covering investors who held $CYDY between March 27, 2020 and March 30, 2022.

A $500,000 settlement has been reached and terms are now submitted to the court for approval.

Who qualifies?

Anyone who held $CYDY during the class period and suffered losses from the alleged misrepresentations about leronlimab's effectiveness for HIV and COVID-19.

Can I still apply?

Yes, you can submit your application now and it will be processed once claims filing officially opens after court approval.

If you were damaged by this don't forget to check your eligibility. GL!

u/JuniorCharge4571 — 13 days ago

▲ 27 r/insiderData+2 crossposts

Oracle insider buying is incredibly rare. Director Stephen Rusckowski just bought $3.5 million, 2.4x the biggest buy in FMP's records since 2005

Last Tuesday (Sep 29), director Stephen Rusckowski bought 25,000 Oracle shares through his living trust. He paid about $139 a share, so ~$3.5 million. Before this he owned 450 shares. It was a regular open-market buy, not a planned one.

So I pulled every open-market buy at Oracle in FMP's records.

Oracle insiders almost never buy. The biggest buy before this was Charles Moorman's ~$1.4 million in March 2020. Rusckowski's buy is 2.4x that!

Does a buy this rare tell you anything, or is it just noise? What do you guys think?

Info pulled through the FMP MCP server:

import asyncio, json
from fastmcp import Client            # pip install fastmcp

KEY = "YOUR_API_KEY"

async def main():
    async with Client(f"https://financialmodelingprep.com/mcp?apikey={KEY}") as fmp:
        result = await fmp.call_tool("insiderTrades", {"endpoint": "search-insider-trades", "symbol": "ORCL",
                                                       "transactionType": "P-Purchase", "limit": 100})
    rows = json.loads(result.content[0].text)

    bought = {}
    for t in rows:
        key = (t["transactionDate"][:7], t["reportingName"])
        bought[key] = bought.get(key, 0) + t["securitiesTransacted"] * t["price"]

    for (month, name), usd in sorted(bought.items(), key=lambda kv: -kv[1])[:5]:
        print(f"{month}  {name}  ${usd:,.0f}")

asyncio.run(main())

Output:

2026-09  RUSCKOWSKI STEPHEN H  $3,483,800
2020-03  MOORMAN CHARLES W  $1,424,162
2022-01  MOORMAN CHARLES W  $1,256,445
2025-02  MOORMAN CHARLES W  $947,913
2021-03  Fairhead Rona Alison  $688,966

reddit.com

u/Bmoses99 — 11 days ago

▲ 25 r/insiderData+1 crossposts

I built a free SEC EDGAR-based screener

I got tired of paying $30–$50/month just to see a company's ratios or balance sheet from 10 years ago, so I built StockNest myself. It's free, no account needed, 120+ metrics. Not monetising it — link in the comments.

Data comes straight from SEC EDGAR filings with reconciliation passes to keep the numbers accurate and consistent.

What it includes:

Compare: chart any combination of metrics across up to 5 tickers simultaneously. 120+ metrics across income statements, balance sheets, cash flows, valuations, and margins. TTM, quarterly, and annual, with YoY / QoQ growth overlays and CAGR across any selected period. 2Y / 5Y / 10Y / All-time ranges go back 25+ years.

Overview: per-ticker overview with a score snapshot, weekly price chart, multiples, median metrics, historical valuation percentile rankings and percentile bands (0th–100th), and valuation range bars (P/E, P/S, P/OCF, P/FCF) with Undervalued / Fairly Valued / Overvalued verdicts. Insider trading transactions, analyst recommendations, congressional and institutional activity all in one tab.

Score: a composite across Profitability, Management, Growth, and Solvency. The badge colour is set by the lowest-scoring category, making potential risk areas immediately visible. Sentiment — analyst ratings, institutional (13F) trades and insider activity — is tracked separately and excluded from the score: it's a signal, not a fundamental, and crowded stocks can underperform.

Filers: track institutional, congressional, and insider trading for any ticker in one place, from Nancy Pelosi to the biggest hedge funds.

Financials: split into Charts, Statements, and Flows. Charts show at-a-glance snapshots — revenue, net income, margins, cash flow. Statements bring the balance sheet, cash flow, income statement, key metrics, and revenue segments into one tab; click any line item to chart it, overlay metrics, and toggle YoY, margins, or absolute values. Flows breaks down how revenue becomes profit and costs.

Screener: filter by 25+ valuation, profitability, return, and health metrics. Sortable results, click any ticker to jump straight into a comparison.

DCF: pre-filled from historical data. Net Income, FCF or OCF. Tune growth rate, decay, terminal multiple, and discount rate. 5Y or 10Y horizon. Non-USD companies show everything in their reporting currency so the comparison stays apples-to-apples.

US-listed companies only for now.

u/rebel-capitalist — 10 days ago

▲ 77 r/insiderData+49 crossposts

Updates for Getting Payment on the Rivian $250 million Settlement

Hey guys, if you missed it, Rivian settled $250 million with investors over claims that it failed to disclose the true cost of producing its vehicles. And, I just found out that they’re accepting claims even though the deadline has passed.

Quick recap: In 2022, Rivian was accused of misleading investors about its vehicle pricing and production costs. In short, the company promoted its R1T pickup and R1S SUV as competitively priced electric vehicles, but investors later alleged that Rivian was losing substantial amounts of money on each vehicle sold and failed to clearly disclose how severe the cost gap was. As supply-chain issues and material costs increased, Rivian announced major price hikes that sparked customer backlash and raised concerns about the company’s financial outlook.

Now, the good news is that the company agreed to settle $250 million with them, and even though the deadline has passed recently, they’re accepting late claims.

So, if you invested in $RIVN when all of this happened, you can still check the details and file your claim here.

Anyway, has anyone here invested in $RIVN at that time? How much were your losses, if so?

u/11thestate — 14 days ago